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ATM, CHEK2, and PALB2 are considered to be moderate-penetrance breast cancer susceptibility 
genes (MPBCSGs). MPBCSG mutation-carriers are predicted to have a lower risk for breast cancer than 
carriers of mutations in genes such as BRCA1, BRCA2, and other high-penetrance breast cancer 
susceptibility genes. Ninety-one practicing genetic counselors were surveyed to investigate genetic 
counselor utilization of the NCCN guidelines and recommendations for carriers of ATM, PALB2, and 
CHEK2 based on personal and family history of breast cancer. Although the majority indicated that they 
would follow the guidelines regardless of personal or family history of breast cancer, some genetic 
counselor recommendations exceeded NCCN guidelines when there was a personal and/or family history 
of breast cancer for an individual with a MPBCSG mutation. For counselors that said they would exceed 
the NCCN guidelines, additional recommendations included consideration of risk-reducing mastectomy, 
bilateral risk-reducing mastectomy, increased screening for relatives, a referral to a breast surgeon, and 
use of risk models to clarify breast MRI recommendations. Our study is the first to report trends in the 
field regarding approaches to providing genetic counseling regarding ATM, CHEK2, and PALB2. The 
results demonstrate that personal/family history of breast cancer is a significant predictor of genetic 
counselor recommendation. 
Key words: ATM, CHEK2, PALB2, breast cancer, moderate-penetrance gene, MPBCSG, genetic 
counseling, NCCN 
Introduction 
The discovery of breast cancer susceptibility genes has had a profound impact on the field of 
genetic counseling since the discovery of BRCA1 and BRCA2 in the 1990s (Miki et al., 1994; Wooster et 
al., 1995; Wooster et al., 1994; Antoniou et al., 2003). Patients with family or personal medical histories 
suggestive of hereditary breast and ovarian cancer syndrome (HBOC) are now regularly offered genetic 
counseling and testing for BRCA1 and BRCA2 gene mutations (Economopoulou, Dimitriadis, & Psyrri, 
2015). Comprehensive, evidence-based clinical practice guidelines for surveillance and management in 




patients with BRCA1/2 mutations as well as other, rarer high-penetrance breast cancer susceptibility gene 
mutations such as TP53, PTEN, STK11, and CDH1 are regularly established and updated by the National 
Comprehensive Cancer Network (NCCN, 2019). 
Within the past decade, next-generation sequencing platforms have facilitated the identification of 
novel breast cancer susceptibility genes considered to confer moderate breast cancer risk. Multi-gene 
panels have been updated to include moderate-penetrance breast cancer susceptibility genes (MPBCSGs), 
and in one study, approximately 2-5% of individuals referred for clinical genetic testing were identified to 
carry a MPBCSG mutation (Tung et al., 2016). While there is a significant need for further research on 
this subset of genes, ATM, CHEK2, and PALB2 are among the most well-studied and commonly tested 
for MPBCSGs in clinical genetics settings (Broeks et al., 2000; Economopoulou, Dimitriadis, & Psyrri, 
2015; Goldgar et al., 2011; Apostolou & Fostira, 2013; Cybulski et al., 2004; Bell et al., 1999; Vahteristo 
et al., 2001; Vahteristo et al., 2002; Cybulski et al., 2011; Xia et al., 2006; Reid et al., 2007; Rahman et 
al., 2007; Antoniou et al., 2014; Southey et al., 2016; Okur & Chung, 2017; Easton et al., 2015). The 
lifetime risk for breast cancer in a woman carrying a mutation in ATM, CHEK2, or PALB2 is estimated to 
be between 20-60% depending on factors such as the gene in consideration, specific pathogenic variant 
identified, and family history of breast cancer (Apostolou & Fostira, 2013; Friedrichsen, Malone, Doody, 
Daling, and Ostrander, 2004; Iniesta et al., 2010; Kuusisto, Bebel, Vihinen, Schleutker & Sallinen, 2011; 
Easton et al., 2015). For example, the CHEK2 pathogenic variant, c.110delC is considered to confer a 
higher risk of breast cancer (The CHEK2 Breast Cancer Case-Control Consortium, 2004; Iniesta et al., 
2010; Schmidt et al., 2016). 
Family history has been considered to be a significant modifier of breast cancer risk in MPBCSG 
mutation carriers. One study of women with truncating variants in CHEK2 estimated the lifetime risk of 
breast cancer to be 20% for a woman with no affected relative, 28% for a woman with an affected second- 
degree relative, 34% for a woman with an affected first-degree relative, and 44% for a woman with 
affected first- and second-degree relatives (Cybulski et al., 2011). For PALB2 mutation carriers, the 




NCCN quotes a breast cancer risk to age 70 of 33% for individuals with no first-degree relatives with 
breast cancer, compared to 58% for individuals with two first-degree relatives (Antoniou et al., 2014). 
Another study mentioned in the NCCN guidelines demonstrated a lower 10-year survival rate associated 
with PALB2 mutation carriers who have breast cancer (Cybulski et al., 2015).  
In 2014, the NCCN added ATM, CHEK2, and PALB2 as new criteria for screening breast MRI 
(Kurian et a., 2017). The NCCN clinical practice guidelines for ATM, CHEK2, and PALB2 mutation 
carriers are fewer and less detailed than the recommendations for individuals identified to carry mutations 
in high-penetrance breast cancer susceptibility genes. Currently, the NCCN breast cancer screening 
guidelines for women identified to carry a mutation include annual mammogram with consideration of 
tomosynthesis and breast MRI with contrast beginning at age 30 for PALB2 mutation carriers and at age 
40 for CHEK2 and ATM mutation carriers. The NCCN states that evidence is insufficient to recommend 
risk-reducing mastectomy (RRM) and advises providers to manage risk based upon family history 
(NCCN, 2019). 
To date, no study has investigated approaches to genetic counseling regarding moderate-
penetrance breast cancer susceptibility genes. It is unknown how consistently genetic counselors follow 
the NCCN guidelines when discussing management recommendations with patients who test positive for 
MPBCSG mutations. In addition, the attitudes of genetic counselors toward providing genetic counseling 
regarding MPBCSGs remains unclear. In this study, we surveyed genetic counselors in order to evaluate 
approaches to providing genetic counseling regarding ATM, CHEK2, and PALB2. We specifically 
investigated counselor attitudes toward the NCCN guidelines and the influence of personal and family 
breast cancer history on the utilization of NCCN guidelines to provide genetic counseling about ATM, 
CHEK2, and PALB2. Given the increasing prevalence of the use of multi-gene panels to test for these 
types of mutations, it is important to evaluate trends in the field of genetic counseling regarding ATM, 
CHEK2, and PALB2. 




We hypothesized that as personal and family history of breast cancer increased in severity, that 
participants may exceed what is recommended by the NCCN guidelines for individuals with MPBCSG 
mutations. We also hypothesized that because PALB2 has been postulated as a high-penetrance breast 
cancer susceptibility gene, there may be an increased tendency to exceed NCCN recommendations in 
these cases. 
Methods 
Participants and Procedures 
 Exempt status for this study was granted by the Sarah Lawrence College Institutional Review 
Board. The survey was distributed via the National Society of Genetic Counselors (NSGC) email blast to 
an estimated 3,300 genetic counselors practicing in the United States and Canada. Board-certified genetic 
counselors providing cancer genetic counseling were eligible to participate in the study. A total of 103 
genetic counselors consented to participate in the survey, and 93 genetic counselors completed the survey. 
91 out of 93 responses were included in our data set. 
Responses of individuals who did not complete the survey in full were not included in our data 
analysis. The additional CHEK2 personal/family history scenario including affected first- and second- 
degree relatives was removed from our data set in order to be consistent in our analysis among genes and 
because there were no differences in responses between the two scenarios which included a family history 
of breast cancer. Because just 2 participants out of 91 indicated that they would recommend less than the 
NCCN guidelines for just 1-2 scenarios, they were removed from our data set. The data regarding the 
severity of gene variants was not analyzed and may be used in a future study. 
Instrumentation 
 An online, anonymous survey was created and distributed using Survey Monkey 
(www.surveymonkey.com). The survey included a consent form followed by 44 questions: four multiple 
choice questions regarding demographics; six multiple choice questions regarding attitudes towards 
counseling regarding ATM, CHEK2, and PALB2; ten questions in which counselors indicated how they 




would manage a case after reviewing a pedigree, eight multiple choice questions about perceived severity 
of ATM, CHEK2, and PALB2 variants, and four spaces to provide additional comments. Pedigrees were 
designed with Progeny. 
A description of the ten questions in which counselors indicated how they would manage a case 
regarding ATM, CHEK2, and PALB2 is displayed in Table 1. For each of these questions, there were three 
personal/family history scenarios: 1) no family history of breast cancer, 2) personal history of breast 
cancer only, and 3) personal and family history of breast cancer. For the personal and family history 
scenario, the affected relative was a 68-year-old mother with breast cancer diagnosed at age 52. For all 
pedigrees, the proband was a 40-year-old woman with a mutation in either ATM, CHEK2, or PALB2.For 
CHEK2, the personal/family history scenarios were expanded to include an additional scenario including 
a personal history of breast cancer and a family history of breast cancer in a first degree relative and a 
second degree relative. The second degree relative was a maternal aunt in her 60s diagnosed with breast 
cancer at age 60. None of the relatives in any scenario had genetic testing results. For all questions of this 
type, genetic counselors were able to review the NCCN guidelines (NCCN Clinical Practice Guidelines in 
Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian) for an individual with the gene 
mutation in consideration and had three answer choices: 1) I would recommend less than what is 
recommended by the NCCN. 2) I would follow the NCCN guidelines. 3) I would recommend more than 
what is recommended by the NCCN. Participants were asked to comment to provide detail if they said 











Table 1. Descriptions of survey questions in which participants were asked to analyze pedigrees 













consider breast MRI 





based on family 
history. 
No family history 1. I would 
recommend less 
than what is 
recommended by 
the NCCN (Please 
comment). 
 




3. I would 
recommend more 
than what is 
recommended by 
the NCCN (Please 
comment). 
2 Personal history only 
3 Personal and family 
history 




consider breast MRI 





based on family 
history. 
No family history 
5 Personal history only 









consider breast MRI 





based on family 
history. 
No family history 
8 Personal history only 
9 Personal and family 
history (1 FDR*) 
10 Personal and family 
history (1 FDRand1 
SDR) 
*FDR = first-degree relative, SDR = second-degree relative 






Figure 1. A sample pedigree utilized for the survey. Genetic counselors were asked to review the 
NCCN guidelines for an individual with a PALB2 mutation, in this case, and decide 
whether they would recommend less than the guidelines, follow the guidelines, or recommend 
more than the guidelines. 
Data Analysis 
Statistical analyses were completed using SPSS version 1.0.0.1131. We conducted 1) a paired t-
test to determine differences in recommendation by gene (ATM, CHEK2, and PALB2) and 2) a paired t-
test to determine differences in recommendation by family history (no family history, personal history 
only, and personal and family history). 
We analyzed differences in genetic counseling among the three MPBCSGs and among the three 
personal/family history scenarios separately. An example of how responses were scored is displayed in 
Table 2 and Table 3. To analyze differences in genetic counselor recommendations among genes, each 
participant was given a score across their responses for each gene. They were given a 1 if they ever 
recommend more than the NCCN guidelines in any scenario for each gene, and they were given a 0 if 




they always indicated that they would follow the NCCN guidelines across all scenarios. To analyze 
differences in genetic counselor recommendations among personal/family history scenarios, participants 
were scored the same way, but across their responses for each personal/family history scenario. 
Table 2. Sample of scoring system used to determine differences in genetic counseling 
recommendations among genes for one participant’s responses. 
ATM No family history (Follow guidelines) 
Personal history only (Follow guidelines) 
Personal and family history (Follow guidelines) 
Summary score 0 
PALB2 No family history (Follow guidelines) 
Personal history only (Follow guidelines) 
Personal and family history (Recommend more) 
Summary score 1 
CHEK2 No family history (Follow guidelines) 
Personal history only (Recommend more) 
Personal and family history (Recommend more) 
Summary score 1 
 
Table 3. Sample of scoring system used to determine differences in genetic counseling 
recommendations among personal/family history scenarios for one participant’s responses. 
No family history ATM (Follow guidelines) 
CHEK2 (Follow guidelines) 
PALB2 (Follow guidelines) 
Summary score 0 
Personal history only ATM (Follow guidelines) 
CHEK2 (Recommend more) 
PALB2 (Follow guidelines) 
Summary score 1 
Personal and family history ATM (Recommend more) 
CHEK2 (Recommend more) 
PALB2 (Recommend more) 












Participant demographics are reported in Table 4. The majority of genetic counselors who 
participated in the survey were cancer genetic counselors with less than 6 years of experience. The 
demographics of the study participants are different from the demographics of the genetic counseling field 
as a whole based on the 2019 Professional Status Survey (PSS) (www.nsgc.org). The sample population 
had more respondents who worked in the cancer specialty than is reported in the PSS, as these individuals 
were part of the target population. In contrast, NSGC region demographics were largely representative of 
data from the PSS. 






































NSGC Region Region 1 (CT, MA, ME, NH, RI, VT, CN Maritime Provinces) 
Region 2 (DC, DE, MD, NJ, NY, PA, VA, WV, PR, VI, Quebec) 
Region 3 (AL, FL, GA, KY, LA, MS, NC, SC, TN) 
Region 4 (AR, IA, IL, IN, KS, MI, MN, MO, ND, NE, OH, OK, SD, WI, Ontario) 
Region 5 (AZ, CO, MT, NM, TX, UT, WY, Alberta, Manitoba, Saskatchewan) 
















Genetic Counselor Attitudes 
 The majority of genetic counselors reported that they were comfortable to very comfortable 
providing genetic counseling regarding ATM, CHEK2, and PALB2 (Figure 2). Almost all participants 
(98.91%) reported that they frequently or always utilize the NCCN guidelines, and 100% of participants 
reported that the NCCN guidelines are at least somewhat helpful when providing genetic counseling 
regarding ATM, CHEK2, and PALB2. When asked about the extent to which they felt the NCCN 
guidelines for ATM, CHEK2, and PALB2 should be changed, 26.88% of participants reported that no edits 
were necessary in their opinion, while 73.12% of participants indicated that they felt the guidelines should 
be edited to contain more information and be more specific. 
 








































Genetic Counselor Recommendations 
Personal/family history was found to be a significant predictor of genetic counselor 
recommendations regarding ATM, PALB2, and CHEK2, as more genetic counselors tended to indicate 
that they would recommend more than the guidelines as personal/family history severity increased 
(Figure 3A). There was a significant difference in the recommendations for no family history and 
personal history only (M=-0.21978, SD=0.41639, t=-5.035, p<0.001) as well as for no family history and 
personal and family history (M=-0.24176, SD=0.45560, t=-5.062, p<0.001). There was no significant 
difference between personal history only and personal and family history (M=-0.02198, SD=0.20966, t=-
1.000, p=0.320). The gene in which the proband had a mutation was not found to be a significant 
predictor of genetic counselor recommendation (Figure 3B). There were no significant differences 
between ATM and PALB2 (M=-0.03297, SD=0.31449, t=-1.000, p=0.320), CHEK2 and PALB2 (M=-
0.04396, SD=0.29485, t=-1.422, p=0.158), or ATM and CHEK2 (M=0.01099, SD=0.018224, t=0.575, 
p=0.567). Despite these findings, the majority of genetic counselors indicated that they would follow the 
NCCN guidelines across all scenarios. 
For those who recommended more than the guidelines for individuals with no family history who 
tested positive for a MPBCSG mutation, many felt that it was reasonable to recommend increased 
screening (i.e., tomosynthesis and breast MRI with contrast) along with risk-reducing mastectomy or 
bilateral mastectomy even though the NCCN guidelines state that evidence is insufficient. Others said that 
they would discuss the increased screening and option of risk-reducing mastectomy with the patient even 
though they personally felt that the NCCN guidelines for management were unnecessary or unjustifiable. 
Also, many participants said that they would engage the patient in a discussion about the difference in 
evidence for risk-reducing mastectomy between individuals with high-penetrance breast cancer 
susceptibility gene mutations (i.e., BRCA1/2) and individuals with mutations in MPBCSGs. Additionally, 
some participants said that they would utilize risk models (i.e., BOADICEA, etc.) to help assess risk and 




recommendations for breast MRI. Others said they would refer the patient to a breast surgeon to discuss 
options for surgical management. 
For those who recommended more than the NCCN for individuals with a personal history of 
breast cancer who tested positive for a MPBCSG mutation, many said that they would recommend risk-
reducing mastectomy or bilateral risk-reducing mastectomy, particularly in individuals with a PALB2 
mutation due to increased risk of contralateral breast cancer. The patient’s age of diagnosis was 
particularly concerning to participants who said they would recommend risk-reducing mastectomy. Many 
also said that they would recommend screening for breast cancer 5-10 years earlier than the age of 
diagnosis of the proband for female family members. A few participants noted the importance of 
assessing patient mental health while discussing the option of risk-reducing mastectomy. Others indicated 
that they understood that the patient may already have had surgeries and treatments for breast cancer and 
would leave the discussion of management recommendations up to the patient’s doctors. Still, some said 
that they would discuss the difference in evidence for risk-reducing mastectomy between individuals with 
high-penetrance breast cancer susceptibility gene mutations (i.e., BRCA1/2) and individuals with 
mutations in MPBCSGs. Furthermore, others said that they would prepare the patient for a discussion 
about risk-reducing mastectomy with a breast surgeon, but highlight that evidence is insufficient for risk-
reducing mastectomy according to the NCCN guidelines. 
For those who recommended more than the NCCN for individuals with a personal history and 
family history of breast cancer who tested positive for a MPBCSG mutation, the reasons for 
recommending more were the same as in the situation where the individual had only a personal history of 
breast cancer. In addition to those recommendations, some participants said that they would offer genetic 
testing for the affected relative. Others said they would discuss the option of pancreatic cancer screening 
in individuals with a PALB2 mutation. 
 




 Figure 3. Percentage of participants indicating that they would recommend more than the 
NCCN guidelines. (A) Differences among personal/family history scenarios for each 
gene. (B) Differences among genes for each personal/family history scenario. 
 
 






Our study aim was to investigate genetic counseling approaches to moderate-penetrance breast 
cancer susceptibility genes (MPBCSGs). Overall, our study elucidated important trends in the field. The 
majority of participants indicated that they would follow the guidelines independently of gene mutation 
and/or personal and family history of breast cancer. However, a number of participants exceeded NCCN 
recommendations in cases where a patient with a MPBCSG mutation had a personal and/or personal and 
family history of breast cancer. 
Participants reported a high level of comfort with providing genetic counseling services regarding 
ATM, CHEK2, and PALB2. All participants indicated a high level of usage of the NCCN guidelines, and 
almost all participants said that the guidelines were at least somewhat helpful when providing genetic 
counseling regarding MPBCSGs. Despite these findings, the majority of participants reported that they 
felt the NCCN guidelines for ATM, PALB2, and CHEK2 should be edited to contain more information 
and be more specific. 
Despite that the majority of participants indicated that they would follow the NCCN guidelines across 
scenarios, the data indicate that personal/family history of breast cancer is a significant predictor of 
whether genetic counselors will recommend more than what is recommended by the NCCN guidelines 
when providing genetic counseling regarding ATM, PALB2, and CHEK2. In contrast, the specific gene in 
consideration was not a significant predictor of genetic counseling recommendations. The results 
demonstrate that participants did not consider the gene in question as highly as the personal/family history 
scenario in question (Figure 3A). For counselors that said they would recommend more than the NCCN 
guidelines, additional recommendations included consideration of risk-reducing mastectomy, bilateral 
risk-reducing mastectomy, increased screening for relatives, a referral to a breast surgeon, and use of risk 
models to clarify breast MRI recommendations. 




We hypothesized that as personal and family history of breast cancer increased in severity, that 
participants may include recommendations that exceed the NCCN guidelines for individuals with 
MPBCSG mutations. This hypothesis was support by our data. We also hypothesized that because PALB2 
has been postulated as a high-penetrance breast cancer susceptibility gene, there would be an increased 
tendency to exceed NCCN recommendations in these cases (Southey et al., 2016; Easton et al., 2015; 
Antoniou et al., 2014). While it seemed that more genetic counselors tended to say they would strongly 
recommend consideration of bilateral risk-reducing mastectomy for individuals with PALB2 mutations 
rather than for individuals with other gene mutations, the difference in genetic counseling 
recommendation among genes was not statistically significant. 
While the small sample size may affect the ability to detect significance, these results demonstrate 
that genetic counselors weigh personal and family history of breast cancer more heavily than the specific 
gene in question when making recommendations for carriers of ATM, PALB2, and CHEK2 mutations. 
Furthermore, our data illustrate that genetic counselors rely on the NCCN guidelines to a great extent 
when counseling about MPBCSGs, but that in a number of cases, exceed NCCN recommendations. 
Overall, our study shows that there is a high level of ambiguity regarding MPBCSG cases. 
Practice Implications 
The study illustrates the current trends in risk counseling regarding ATM, CHEK2, and PALB2.  
The study demonstrated that with an increase in personal and family history of breast cancer, many 
genetic counselors exceed NCCN guidelines, which involves discussion and recommendation about risk-
reducing mastectomy and other interventions. However, we did observe a difference in recommendations 
among our respondents. In the future, this research may provoke the formation of a focus group in which 
genetic counselors may engage with each other and have conversations about risk assessment for 
MPBCSGs on a larger platform.  
A significant barrier to having consistent recommendations is the unavailability of risk data for 
MPBCSGs. One of the ways to overcome this challenge is for clinics and laboratories to share cancer 




phenotypes seen in patients and their families for particular variants in MPBCSGs. This will consequently 
help clinical genetic counselors provide consistent risk counseling and we will hopefully have clearer 
risk-management guidelines for MPBCSGs in future. 
Study Limitations  
This study is limited by the fact that the survey was conducted only among genetic counselors who 
are members of the NSGC and does not include other non-NSGC member genetic counselors, making the 
results non-generalizable. Although the survey was aimed at all genetic counselors who are members of 
the National Society of Genetic Counselors, the response rate was low (2.82%, 93 out of approximately 
3,300 genetic counselors). We also observed a high number of participants who had between 0 and 6 
years of experience, which may not reflect the demographics of the field and may have skewed our data 
set. 
Additionally, our survey does not take into account that patients with a personal history of breast 
cancer may have had a risk-reducing mastectomy already or may have been currently receiving treatment; 
in these cases, it may be inappropriate for a genetic counselor to make management recommendations 
based on the NCCN guidelines. Furthermore, the language for certain questions asked in the survey could 
have been more descriptive. For example, using the phrase “pathogenic variant” instead of “mutation” 
may have clarified our questions. We took note that a few of our respondents had difficulty grasping what 
“more than what is recommended by the NCCN” implied. This might have affected the readability and 
consequently the choice of answer by some participants. 
Furthermore, our data analysis was limited by the use of the SPSS software and the way in which we 
asked our questions. Because we always asked genetic counselors what they would do in the context of 
each gene and each personal/family history scenario, there was no way to decouple the two predictors. 
Furthermore, in order to analyze data across genes, we had to remove the fourth personal/family history 
scenario from the CHEK2 questions. However, there were no participants who had a different response 
for the third personal/family history scenario (personal and family history of breast cancer in a first-




degree relative) than for the fourth scenario (personal and family history of breast cancer in one first-
degree relative and one second-degree relative). Because we needed to transform our data into a binomial 
response data set in order to work with SPSS, we were unable to analyze differences in the number of 
scenarios in which a participant stated that they would recommend more than the guidelines. If they ever 
recommended more in any scenario, they were assigned a 1, and if they always followed the guidelines, 
they were assigned a 0 (Table 2, Table 3). If we were instead able to give scores for each time a 
participant recommended more, (i.e., a score of 2 if the participant recommended more in both the 
personal history only scenario and the personal and family history scenario), then we would have been 
able to enhance the depth of our analysis.  
Research Recommendations  
In this study, we sought to identify the extent to which genetic counselors follow the NCCN 
guidelines in counseling patients that are positive for a known pathogenic variant in ATM, CHEK2, or 
PALB2. Future research could include a larger sample population that provides a more generalizable 
representation from the majority of genetic counseling community. The data could also be used to infer if 
the counseling recommendation is dependent on the years of experience in cancer genetic counseling 
practice. 
Furthermore, our pedigree questions included patients that were either negative for or positive for a 
personal history of breast cancer. It might be more beneficial to understand the approach of counseling 
towards an unaffected patient with an affected first-degree relative, both carrying a pathogenic variant in a 
MPBCSG. 
Currently, the NCCN guidelines state that genetic counselors should manage individuals who test 
positive for mutations in MPBCSGs based on family history (NCCN, 2019). Given the plethora of 
variability in family history, it may be helpful to include specific recommendations based on degrees of 
relationship, number of family members affected with cancer, cancer diagnoses and ages at diagnosis, etc. 
in order to better provide counseling regarding surgical intervention.  




Finally, this research survey included questions about genetic counselors' risk-assessment for specific 
known pathogenic variants in the MPBCSGs, which were not included in the final results. As new data 
about these variants emerges, it will be useful to study if genetic counselors base their risk assessment and 
recommendations on specific variants within MPBCSGs. 
 
Conclusions 
 Our study is the first to report trends in the field regarding approaches to providing genetic 
counseling regarding ATM, CHEK2, and PALB2. The results demonstrate that personal/family history of 
breast cancer is a significant predictor of genetic counselor recommendation. A number of genetic 
counselors’ recommendations exceeded NCCN guidelines in cases where a person with a mutation had a 
personal history or personal and family history of breast cancer. The moderate-penetrance gene in 
question was not a significant predictor of genetic counseling recommendation. Despite these findings, 
the majority of participants indicated that they would follow the NCCN guidelines in across scenarios. 
Overall, the study highlights the ambiguity in genetic counseling regarding ATM, CHEK2, and PALB2 
and suggests that it may be helpful for the NCCN to provide more direction for genetic counseling in 
















All procedures followed were in accordance with the ethical standards of the responsible 
committee on human experimentation (institutional and national) and with the Helsinki Declaration of 
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